Company profile: Lineagen
1.1 - Company Overview
Company description
- Provider of diagnostic and healthcare services for complex genetic diseases, offering FirstStepDx PLUS chromosomal microarray to identify genomic deletions/duplications associated with autism spectrum disorder, developmental delay, intellectual disability, congenital anomalies, dysmorphic features, and epilepsy; NextStepDx PLUS whole exome sequencing; genetic counseling; and optical genome mapping data services.
Products and services
- NextStepDx PLUS: Whole-exome test identifies disease-causing variants by analyzing all protein-coding regions of the human genome for individuals with autism, developmental delay, intellectual disability, epilepsy, or suspected genetic disorders
- FirstStepDx PLUS: Chromosomal microarray-based test pinpoints genomic deletions and duplications associated with autism spectrum disorder, developmental delay, intellectual disability, congenital anomalies, dysmorphic features, and epilepsy
- Optical Genome Mapping (OGM) Data Services: Genome-wide research projects analyze samples using optical genome mapping to detect structural variations with high sensitivity across the genome.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lineagen
Amylyx Pharmaceuticals
HQ: United States
Website
- Description: Provider of solutions for Alzheimer’s and other brain diseases, offering ALS treatments such as RELYVRIO (U.S.)/ALBRIOZA (Canada) and AMX0035, a combination of sodium phenylbutyrate and taurursodiol studied for ALS and other neurodegenerative diseases, plus a patient support program with assistance and a free drug program for eligible patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amylyx Pharmaceuticals company profile →
Onward
HQ: The Netherlands
Website
- Description: Provider of an implantable neuro-stimulation system (INS) with real-time motion feedback and training tools to rehabilitate patients with neurological disorders, including spinal cord injury (SCI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onward company profile →
Vitro Biopharma
HQ: United States
Website
- Description: Provider of stem cell therapy, cell lines, and cell culture media, including AlloRx Stem Cell therapy from Wharton’s jelly–derived MSCs for autoimmune and inflammatory disorders; MSC-Gro specialty media for MSC growth and expansion; research-grade cancer-associated and native fibroblasts; human umbilical cord and placenta-derived MSC lines; and MSC-Gro formulations (low serum, serum-free, CAF-specific).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitro Biopharma company profile →
Annexon Biosciences
HQ: United States
Website
- Description: Provider of complement-targeting therapeutics focused on C1q, including ANX005 to inhibit the classical complement pathway for autoimmune and neurodegenerative disorders; ANX007, an intravitreal therapy for glaucoma and other ophthalmic conditions; ANX009, a subcutaneous therapy for systemic autoimmune diseases; and ANX1502, an early-stage candidate for complement-mediated diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annexon Biosciences company profile →
BioArctic
HQ: Sweden
Website
- Description: Provider of research-oriented biopharma solutions focused on neurodegenerative diseases, including Lecanemab—an antibody targeting amyloid-beta oligomers and protofibrils for Alzheimer’s—R&D of treatments addressing the cause of nerve cell damage in Parkinson’s disease and ALS, and brain transporter technology to enable drug delivery across the blood-brain barrier.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioArctic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lineagen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lineagen
2.2 - Growth funds investing in similar companies to Lineagen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lineagen
4.2 - Public trading comparable groups for Lineagen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →